Regeneron Pharmaceuticals (REGN) Stock Price, Quote & News

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascul...

Industry: Biotechnology

Sector: Healthcare

Phone: 914 847 7000

Website: www.regeneron.com

Address:

777 Old Saw Mill River Road, Tarrytown, United States

TwongStocks Mar. 6 at 10:20 PM

$REGN $SRRK INCY SEC filing today. They confirmed they received a CRL on Feb 27 due to the Catalent Indiana facility. https://www.sec.gov/ix?doc=/Archives/edgar/data/0000879169/000087916926000013/incy-20260227.htm Appears that the Catalent Indiana still has issues.

1 · Reply

TheRealShortSqueezy Mar. 6 at 2:40 PM

$SCNI: Can the March 2 News Spark the Next Move? March 2 News: Scinai Immunotherapeutics announced it amended its PinCell acquisition option and submitted a revised €12M non-dilutive grant application to advance the PC111 antibody program, with a funding decision expected in 3–4 months. 📊 Technical view: ▪️ Major support: ~$0.80 ▪️ Price stabilizing near range lows ▪️ Short-term bounce forming 📈 Reclaim levels to watch: ▪️ $0.97 first resistance ▪️ $1.12 next breakout level ▪️ $1.31 supply zone ▪️ $1.54–$1.63 major resistance ▪️ $1.96+ momentum breakout If support holds and volume builds, SCNI could attempt a trend reversal from this base. 📈 Sector Peers: $BNTX $MRNA $REGN $AMGN

0 · Reply

Tfizzle Mar. 5 at 10:00 PM

$HLNE $WHR $REGN awesome day. Stalking $COLL for tomorrow

0 · Reply

Quantumup Mar. 5 at 1:09 PM

H.C. Wainwright⬆️ $EYPT to $30 and reiterated at Buy after the Co reported 4Q/FY finacial results/announced earlier this week that the Ph3 trials of DURAVYU in DME had dosed the first patients. $OCUL $REGN $RHHBY FDMT KOD $SRZN H.C. Wainwright said—Management noted that DURAVYU could potentially address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME. Both COMO and CAPRI trials could report topline data in 2H27, according to management. In the wake of this update, we have included the Phase 3 DME program in our valuation and our estimated market value of the firm has increased to $2.51B, or approximately $30 per share. Therefore, we reiterate our Buy rating while raising our 12-month price target to $30 from $23 per share.

0 · Reply

Unicorn2020 Mar. 4 at 8:32 PM

$NTLA Regeneron is already a major collaborator with Intellia, specifically on NTLA-2001 for ATTR amyloidosis. Both have a long-standing partnership, and it has been speculated in the market that $REGN could look to acquire the remaining stake in Intellia to bring this in-vivo CRISPR technology completely in-house. Given the high-risk, high-reward nature of gene editing, other large pharmaceutical companies looking for exposure to CRISPR/Cas9 technologies could be potential buyers. This shell offering can be a hint: the potential acquirer are buying all these shares.

3 · Reply

Quantumup Mar. 4 at 8:05 PM

Chardan⬆️the PT on $EYPT to $29 from $27 and reiterated at a Buy rating. $OCUL $REGN RHHBY $SRZN KOD $FDMT Chardan said in its note—EyePoint reported 4Q25 financial results and provided updates on its Duravyu programs. The company ended the quarter with cash, cash equivalents, and marketable securities of $306 mm, with the projected operational runway into 4Q27. Updating our forward estimates raises our PT to $29 from $27. The next big catalyst for EyePoint is the Phase 3 Duravyu data from LUGANO and LUCIA trials in mid-2026. Our confidence in this program remains high, supported by robust Phase 2 data and the recently reported SOL-1 data from Ocular Therapeutics (Buy), which, we believe, provides further validation of the TKI MoA in wet AMD.

0 · Reply

Quantumup Mar. 2 at 9:16 PM

Clear Street⬆️ $OCUL to $28/reiterated at Buy, plus⬆️LoS to 65%. $EYPT $REGN RHHBY $KOD $SRZN Here's what Clear Street said: https://x.com/Quantumup1/status/2028579385851187401?s=20

0 · Reply

StockMomentumLab Mar. 2 at 6:11 PM

$OCUL William Blair reiterates Outperform following positive SOL-1 top-line data for Axpaxli in wet AMD. 👉Click to view @StockMomentumLab for timely updates amid the volatility. Takeaways: • SOL-1 supports durability + efficacy profile • SOL-R readout expected Q1 2027 • Company planning near-term NDA submission • HELIOS-3 launch signals pipeline expansion Blair sees potential for Axpaxli to be a meaningful advance in nAMD, with possible blockbuster upside if data continues to deliver. Eyes now on regulatory path + SOL-R execution. $EYPT $REGN Roche Holding $SRZN $KOD

2 · Reply

ZacksResearch Mar. 2 at 5:57 PM

$REGN & $SNY just opened the door to a fresh growth catalyst 🚀 Dupixent snagged CHMP backing to expand into pediatric CSU — and with EU and U.S. decisions ahead, this could unlock an entirely new growth avenue for the franchise. That’s how pipelines quietly turn into long-term revenue engines. Are you positioned before the next regulatory domino falls? Full breakdown here 👉 https://www.zacks.com/stock/news/2877349/regn-snys-dupixent-gets-chmp-nod-for-pediatric-use-in-urticaria?cid=sm-stocktwits-2-2877349-teaser-35764&ADID=SYND_STOCKTWITS_TWEET_2_2877349_TEASER_35764

0 · Reply

StockMomentumLab Mar. 2 at 5:30 PM

$OCUL $REGN EYLEA HD is showing strong clinical results — comparable vision gains to standard EYLEA (2 mg) for wet AMD, DME, RVO, but with fewer injections thanks to longer dosing intervals. 👉Click to view @StockMomentumLab for timely updates amid the volatility. Trials PULSAR & PHOTON indicate most patients maintain improvements on 12–16 week cycles, cutting down treatment burden significantly. This could be a game-changer for patient compliance and clinic capacity, offering the same efficacy with less frequent visits. Eyes on adoption and upcoming regulatory updates — potential upside in both clinical and commercial execution.

0 · Reply

Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Feb 28, 2026, 8:10 AM EST - 7 days ago

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

AIO AMGN CVX EIC EOD EOS GAM

Feb 27, 2026, 8:00 AM EST - 8 days ago

Why Dupixent Keeps Regeneron A Top Big Pharma Pick

Feb 27, 2026, 7:03 AM EST - 8 days ago

Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

SNY

Feb 27, 2026, 7:00 AM EST - 8 days ago

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

Feb 24, 2026, 1:47 PM EST - 11 days ago

Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition

SNY

Feb 24, 2026, 9:30 AM EST - 11 days ago

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Feb 24, 2026, 9:30 AM EST - 11 days ago

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

SNY

Feb 19, 2026, 7:00 AM EST - 16 days ago

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Feb 17, 2026, 7:08 AM EST - 18 days ago

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

OCUL

Feb 13, 2026, 5:45 AM EST - 22 days ago

Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells

ASML BABA BEKE BEPC GOOG GOOGL INCY

Feb 11, 2026, 4:05 PM EST - 24 days ago

Regeneron Announces Investor Conference Presentations

Feb 10, 2026, 7:00 AM EST - 25 days ago

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

Feb 2, 2026, 12:13 PM EST - 4 weeks ago

These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

Feb 2, 2026, 7:00 AM EST - 4 weeks ago

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

Jan 31, 2026, 8:33 AM EST - 5 weeks ago

Regeneron: Expect Double-Digit Growth In 2026

Jan 30, 2026, 3:10 PM EST - 5 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript

Jan 30, 2026, 12:42 PM EST - 5 weeks ago

Regeneron bets added cholesterol benefit will help its obesity drug stand out

Jan 30, 2026, 10:56 AM EST - 5 weeks ago

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Jan 30, 2026, 7:37 AM EST - 5 weeks ago

Regeneron beats quarterly profit estimates on Dupixent strength

Jan 30, 2026, 6:30 AM EST - 5 weeks ago

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Jan 30, 2026, 4:10 AM EST - 5 weeks ago

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Jan 23, 2026, 3:25 PM EST - 6 weeks ago

Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026

Jan 21, 2026, 12:05 PM EST - 6 weeks ago

Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

Jan 12, 2026, 8:16 PM EST - 7 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 1:30 PM EST - 7 weeks ago

Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba

BABA COF UNH

Jan 7, 2026, 4:18 PM EST - 2 months ago

Regeneron Just Moved From Underperform To Buy - Here's Why

Dec 23, 2025, 1:00 AM EST - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

SNY

Dec 23, 2025, 1:00 AM EST - 2 months ago

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Dec 22, 2025, 4:05 PM EST - 2 months ago

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Dec 20, 2025, 9:30 AM EST - 2 months ago

Regeneron: The Turnaround Is Gaining Steam

Dec 10, 2025, 1:31 PM EST - 3 months ago

Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv

BKNG FISV GD

Dec 10, 2025, 12:42 PM EST - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript

Dec 10, 2025, 12:20 PM EST - 3 months ago

Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial

Dec 8, 2025, 2:46 PM EST - 3 months ago

Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?

Dec 7, 2025, 4:30 PM EST - 3 months ago

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Dec 6, 2025, 9:33 AM EST - 3 months ago

Regeneron's experimental therapy combo effective in untreated cancer patients

Dec 3, 2025, 2:13 PM EST - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 4:53 PM EST - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 1, 2025, 7:00 AM EST - 3 months ago

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Nov 25, 2025, 1:00 AM EST - 3 months ago

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Nov 25, 2025, 1:00 AM EST - 3 months ago

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

SNY

Nov 21, 2025, 11:05 AM EST - 3 months ago

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

LLY

Nov 20, 2025, 11:52 AM EST - 3 months ago

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

Nov 19, 2025, 4:10 PM EST - 3 months ago

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Nov 19, 2025, 7:00 AM EST - 3 months ago

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Nov 17, 2025, 1:07 PM EST - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 17, 2025, 11:57 AM EST - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 13, 2025, 7:00 AM EST - 4 months ago

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Nov 12, 2025, 6:20 PM EST - 4 months ago

Final Trade: LMAT, REGN, BA, TJX

TJX BA LMAT

TwongStocks Mar. 6 at 10:20 PM

1 · Reply

TheRealShortSqueezy Mar. 6 at 2:40 PM

0 · Reply

Tfizzle Mar. 5 at 10:00 PM

$HLNE $WHR $REGN awesome day. Stalking $COLL for tomorrow

0 · Reply

Quantumup Mar. 5 at 1:09 PM

0 · Reply

Unicorn2020 Mar. 4 at 8:32 PM

3 · Reply

Quantumup Mar. 4 at 8:05 PM

0 · Reply

Quantumup Mar. 2 at 9:16 PM

Clear Street⬆️ $OCUL to $28/reiterated at Buy, plus⬆️LoS to 65%. $EYPT $REGN RHHBY $KOD $SRZN Here's what Clear Street said: https://x.com/Quantumup1/status/2028579385851187401?s=20

0 · Reply

StockMomentumLab Mar. 2 at 6:11 PM

2 · Reply

ZacksResearch Mar. 2 at 5:57 PM

0 · Reply

StockMomentumLab Mar. 2 at 5:30 PM

0 · Reply

Quantumup Mar. 2 at 5:06 PM

William Blair reiterated $OCUL at an Outperform rating. $EYPT $REGN RHHBY $SRZN $KOD Here's what William Blair had to say: https://x.com/Quantumup1/status/2028516173059690609?s=20

0 · Reply

ZacksResearch Mar. 2 at 4:57 PM

$REGN riding high with a promising CHMP nod for Dupixent expansion! 🚀 👶 Positive recommendation for treating children aged 2 to 11 with chronic spontaneous urticaria, backed by solid Phase III data. 💡 The drug already shows a strong track record in other conditions globally. See what this means for REGN investors 👉 https://www.zacks.com/stock/news/2877349/regn-snys-dupixent-gets-chmp-nod-for-pediatric-use-in-urticaria?cid=sm-stocktwits-2-2877349-body-35763&ADID=SYND_STOCKTWITS_TWEET_2_2877349_BODY_35763

0 · Reply

judgeyoung2 Mar. 2 at 4:20 PM

$REGN continue to do weekly strangles on this for the melanoma data. only do far otm and don’t spend more than .20 on each contract.

1 · Reply

Estimize Mar. 2 at 4:03 PM

Wall St is expecting 9.16 EPS for $REGN Q1 [Reporting 04/30 BMO] http://www.estimize.com/intro/regn?chart=historical&metric_name=eps&utm_co

0 · Reply

trading_momentum_x Mar. 2 at 1:46 PM

$REGN IHS setup still setting up. Long shares and will be watching for $740 retest to enter calls. Healthcare outperformance still in early inning $IMHO $LLY $MRK $KVUE BMY

0 · Reply

WallStreetBuyDip Mar. 2 at 7:24 AM

$GILD trading at $149 with volume 42% above average, while $REGN at $782 with volume 32% below average. GILD showing 12% gain compared to REGN's 8% move. Both in Healthcare - what's the next prescription for these stocks?

0 · Reply

ZacksResearch Feb. 27 at 5:14 PM

$NTLA climbs 6.4% on Q4 earnings beat! 🚀 Loss narrowed to 83 cents vs. Zacks Consensus of 99 cents, and Q4 revenues soared 73.8%, driven by collaborations with $REGN and the termination of the agreement with SparingVision. See the full breakdown here 👉 https://www.zacks.com/stock/news/2876870/intellia-rises-on-q4-earnings-revenue-beat-focuses-on-pipeline?cid=sm-stocktwits-2-2876870-body-35561&ADID=SYND_STOCKTWITS_TWEET_2_2876870_BODY_35561

0 · Reply

judgeyoung2 Feb. 27 at 1:52 AM

$REGN drop the data god damn it

0 · Reply

Iwannagofast1 Feb. 26 at 4:55 PM

$REGN Buying another 150 shares right here

0 · Reply

Whiskeyunderthebed Feb. 26 at 3:52 PM

$REGN what a joke on this take down.

0 · Reply

merlernin Feb. 25 at 6:01 PM

$IBRX $BIB $GILD $JNJ $REGN

0 · Reply

macrossluvsrobotech Feb. 25 at 5:12 PM

$IBRX THIS IS ALL GETTING BAKED IN. If this comes out positive, gues what happens to all the shorts here... know before you play. And if data isn't exactly what we want, as per standard of care, we still print money for bulls, because we are still growing in revenues and our Anktiva WORKS FANTASTIC. IT'S WIN WIN FOR BULLS. If it goes down, it's a perfect buying opportunity for bulls. The Godamn drug works!!! This study will add extra perks that can make it 'standard of care' or an adjacent. Either way: BULLS MAKE MONEY. Shorts STILL DONT WIN IF the data isn't exactly for standard of care, because the GODAMN TREATMENT WORKS, EITHER WAY, AS A SUPPLEMENT BY DISCRETION, WHICH WILL HAPPEN BY DEFAULT AS DOCTORS KNOW OF ITS EFFECTIVENESS. $BIB $GILD $REGN $MRK

1 · Reply

Market Cap	80.33B
Revenue (ttm)	14.34B
Net Income (ttm)	4.50B
EPS (ttm)	N/A
PE Ratio	21.20
Forward PE	21.93
Profit Margin	31.41%
Debt to Equity Ratio	0.06

Volume	561,900
Avg Vol	774,874
Day's Range	N/A - N/A
Shares Out	105.72M
Stochastic %K	27%
Beta	0.41
Analysts	Strong Sell
Price Target	$871.12